Pharmanovia, a leading popular pharmaceutical company that markets the novel speciality drugs and the trusted developed medicines, has now introduced its Korjuny (Catumaxomab) in Germany. This new launch has made the T-cell connector trifunctional antibody drug the first ever and the only one of the pharmacological treatments for malignant ascites (MA) for people struggling and still living with these extreme and stressful conditions across the globe.
After obtaining the proprietary rights to launch, promote and market the catumaxomab last year, in collaboration with Lindis Biotech. From then, the Pharmanovia has been dedicated to delivering access to the treatment to an infinite number of individuals to help them mitigate the symptom burden and the severity that hammers their lives.
Catumaxomab, a robust first-in-class therapeutic, is mainly built to treat malignant ascites in adults with a few types of cancer, who are not qualified for other systemic anticancer therapies. Malignant ascites is an extreme level of complication, a disturbance of advanced-stage cancers that is classified by the formation of fluid in the abdomen. This causes discomfort and adversely affects the quality of life. This problem leads to obvious symptoms like pain, fatigue, fever, shortness of breath and abdominal distension.
The Chief Scientific Officer at Pharmanovia, Stephen Deacon, said, “The introduction of catumaxomab represents a crucial step for tons of individuals with malignant ascites in Germany. It’s a problem where the latest standard of care is frequently recurrence and palliative, also the hospital visits are just normal. By focusing on tumor cells and considering the immune system, catumaxomab provides a novel idea engineered to identify the underscored pathophysiology rather than just detecting the symptoms. This approach will mitigate individuals from the storm of the symptom burden.”
The CEO at Pharmanovia, Stephan Eder, while stressing the wide range of implications of the launch of this best-in-class treatment, said, “The entry of catumaxomab in Germany is a crucial step for individuals with malignant ascites. Mainly for those German individuals who had no pharmaceutical treatment options earlier. It’s a relief for them and an advantage for Pharmanovia’s growth in speciality oncology.”
“By introducing this therapy to the market space, we’re illustrating the power of our dedication to serve value for healthcare systems and patients as well by opening gates for novel treatment options.”
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
